Skip to main content
Equibles
RVMD logo

RVMD · Revolution Medicines, Inc. · Webcasts, Transcripts & Audio

Track RVMD — free

Use RVMD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RVMD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$205.89 +0.63 (+0.31%) At close · Oct 1
Russell 1000 member Rebalance outlook locked
Market Cap
$43.93B
Shares
214.34M
Volume · Oct 1 2.1M Avg daily vol (3M) 1.94M

Revolution Medicines, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Revolution Medicines, Inc. (RVMD), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲204.8% $3.36M −$73.33M '22 Q3 22-11-07 ▲62.1% $15.33M −$56.51M '22 Q4 23-02-27 ▼7.4% $7.01M −$68.10M '23 Q1 23-05-08 ▼58.1% $3.82M −$98.30M '23 Q2 23-08-08 ▼100% $ −$108.43M '23 Q3 23-11-06 ▼95.2% $742,000 −$161.54M '23 Q4 24-02-26 ▼100% $ −$116.00M '24 Q1 24-05-08 ▼100% $ −$133.23M '24 Q2 24-08-07 · $ −$156.29M '24 Q3 24-11-06 LATEST ▼100% $ −$194.57M '24 Q4 25-02-26
Earnings call
FY26 · Q2
2026-08-05
Revolution Medicines, Inc. (RVMD) Q2 2026 Earnings Call Transcript
Confident tone Expanded Access Program (EAP) Pancreatic cancer / PDAC launch Regulatory progress
Diluted EPS
$-3.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-05-31
Revolution Medicines, Inc. (RVMD) May 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Revolution Medicines, Inc. (RVMD) Q1 2026 Earnings Call Transcript
Confident tone RASolute 302 Phase 3 results in pancreatic cancer Pipeline of RAS(ON) inhibitors and combination strategies Clinical and competitive uncertainties
Diluted EPS
$-2.29
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Revolution Medicines, Inc. (RVMD) Q4 2025 Earnings Call Transcript
Confident tone Daraxonrasib in pancreatic cancer (RASolute 302/303/304) Zoldonrasib development in PDAC RMC-6236 (daraxonrasib) combination strategies
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Revolution Medicines, Inc. (RVMD) Q3 2025 Earnings Call Transcript
Confident tone Daraxonrasib in pancreatic cancer (PDAC) Combination strategies and resistance mechanisms Efficacy and durability data
Diluted EPS
$-1.61
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Revolution Medicines, Inc. (RVMD) Q2 2025 Earnings Call Transcript
Confident tone Pancreatic cancer program (daraxonrasib) Non-small cell lung cancer (NSCLC) Clinical collaborations and combinations
Diluted EPS
$-1.31
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Revolution Medicines, Inc. (RVMD) Q1 2025 Earnings Call Transcript
Confident tone Non-small cell lung cancer strategy RAS(ON) inhibitor portfolio Pancreatic cancer development
Diluted EPS
$-1.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Revolution Medicines, Inc. (RVMD) Q4 2024 Earnings Call Transcript
Confident tone RAS(ON) inhibitor pipeline progress Combination strategies Pivotal/registrational trials execution
Revenue
$*
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript
Confident tone RMC-6236 in pancreatic cancer (PDAC) Combination strategy and clinical collaborations Non-small cell lung cancer strategy
Revenue
$
Diluted EPS
$-0.94
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Revolution Medicines, Inc. (RVMD) Q2 2024 Earnings Call Transcript
Confident tone RMC-6236 pancreatic cancer data and registrational plans Combination studies and early-line expansion RAS(ON) mutant-selective inhibitors (RMC-6291, RMC-9805)
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.81
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Revolution Medicines, Inc. (RVMD) Q1 2024 Earnings Call Transcript
Confident tone RMC-6236 combination regimens RMC-6236 pivotal trial strategy RMC-6291 and RMC-9805 mutant-selective inhibitors
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.70
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-26
Revolution Medicines, Inc. (RVMD) Q4 2023 Earnings Call Transcript
Confident tone RMC-6236 pivotal trial plans Financial strength and runway RMC-6291 G12C selective inhibitor
Revenue
$742,000*
▼ 95.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Revolution Medicines, Inc. (RVMD) Q3 2023 Earnings Call Transcript
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.99
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Revolution Medicines, Inc. (RVMD) Q2 2023 Earnings Call Transcript
Revenue
$3.82M
▼ 58.1% YoY
Diluted EPS
$-0.92
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Revolution Medicines, Inc. (RVMD) Q1 2023 Earnings Call Transcript
Revenue
$7.01M
▼ 7.4% YoY
Diluted EPS
$-0.72
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-27
Revolution Medicines, Inc. (RVMD) Q4 2022 Earnings Call Transcript
Revenue
$15.33M*
▲ 62.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Revolution Medicines, Inc. (RVMD) Q3 2022 Earnings Call Transcript
Revenue
$3.36M
▲ 204.8% YoY
Diluted EPS
$-0.87
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Revolution Medicines, Inc. (RVMD) Q2 2022 Earnings Call Transcript
Revenue
$9.12M
▲ 4.8% YoY
Diluted EPS
$-0.82
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Revolution Medicines, Inc. (RVMD) Q1 2022 Earnings Call Transcript
Revenue
$7.58M
▼ 25.2% YoY
Diluted EPS
$-0.78
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-11
Revolution Medicines, Inc. (RVMD) Q4 2021 Earnings Call Transcript
Revenue
$9.46M*
▲ 8.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Revolution Medicines, Inc. (RVMD) Q3 2021 Earnings Call Transcript
Revenue
$1.10M
▼ 91.3% YoY
Diluted EPS
$-0.72
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
Revolution Medicines, Inc. (RVMD) Q2 2021 Earnings Call
Revenue
$8.70M
▼ 13.2% YoY
Diluted EPS
$-0.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–22 of 22 webcasts
Key facts CIK 1628171 CUSIP 76155X100 13F (30d) 19 filings 16 filers Visit website Investor relations